6615.TWO Sofiva Genomics Co.,Ltd.
- Market cap
- TWD 708M
- P/E
- 49.7x
- P/B
- 1.09x
- ROE
- 6.2%
- Dividend yield
- 0.91%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 6615.TWO undervalued?
Graham number6615.TWO trades 55.0% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sofiva Genomics Co.,Ltd. fundamental analysis
No fundamental analysis for Sofiva Genomics Co.,Ltd. yet.
Sofiva Genomics Co.,Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sofiva Genomics Co.,Ltd.
Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M); and prenatal testing services, such as non-invasive prenatal screening, array…
Full company profileSofiva Genomics Co.,Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sofiva Genomics Co.,Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 508M | 496M | 467M | 453M | 386M | 380M |
| Gross Profit | 177M | 149M | 130M | 136M | 99.1M | 106M |
| Operating Income | 35.1M | 3.30M | -15.9M | -3.37M | -33.7M | -8.52M |
| EBITDA | - | 91.6M | 51.5M | 66.3M | 34.1M | 83.2M |
| Net Income | 57.0M | 42.8M | 11.5M | 18.4M | -9.36M | 39.9M |
| EPS | 2.67 | 2.00 | 0.54 | 0.85 | -0.43 | 1.85 |
| Balance Sheet | ||||||
| Total Assets | 822M | 808M | 767M | 768M | 724M | 736M |
| Total Liabilities | 198M | 180M | 149M | 124M | 95.9M | 87.7M |
| Shareholders' Equity | 624M | 627M | 618M | 644M | 628M | 648M |
| Cash & Short-term Investments | 215M | 120M | 96.8M | 112M | 90.6M | 97.4M |
| Cash Flow | ||||||
| Operating Cash Flow | 80.1M | 17.1M | 23.7M | 34.7M | 15.4M | 24.2M |
| Capital Expenditure | 12.7M | 35.7M | 24.6M | 24.1M | 8.15M | 14.2M |
| Free Cash Flow | 67.4M | -18.6M | -859K | 10.6M | 7.20M | 10.0M |
| Ratios | ||||||
| ROE | 9.1% | 6.8% | 1.9% | 2.9% | -1.5% | 6.2% |
| ROA | 6.9% | 5.3% | 1.5% | 2.4% | -1.3% | 5.4% |
| Net Profit Margin | 11.2% | 8.6% | 2.5% | 4.1% | -2.4% | 10.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Sofiva Genomics Co.,Ltd. dividends
- Dividend yield
- 0.91%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Jun 27, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 6.48M | 0.30 | - |
| 2024 | TWD 4.27M | 0.20 | 23.2% |
| 2023 | TWD 21.4M | 1.00 | 185.3% |
| 2022 | TWD 42.7M | 2.00 | 99.9% |
| 2021 | TWD 29.8M | 1.39 | 52.2% |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sofiva Genomics Co.,Ltd.
- Insiders 48.48%
- Institutions 0.00%
- Public & others 51.52%
- Shares outstanding 21.6M
- Free float 12.6M
Sofiva Genomics Co.,Ltd. company profile
- Company name
- Sofiva Genomics Co.,Ltd.
- Ticker
- 6615.TWO
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Fiscal year end
- December
- Address
- No. 66-1, Chongqing S. Road, Taipei, Taiwan, 100
- Phone
- 886 2 2382 6615
- Website
- sofivagenomics.com.tw
About Sofiva Genomics Co.,Ltd.
Sofiva Genomics Co.,Ltd. provides pre-pregnancy, prenatal, and newborn genetic testing and medical testing services in Taiwan and internationally. The company offers reproductive testing services, including preimplantation genetic testing for aneuploidy (PGT-A), non-invasive preimplantation genetic testing for aneuploidy (niPGT-A), and preimplantation genetic testing for monogenic diseases (PGT-M); and prenatal testing services, such as non-invasive prenatal screening, array, karyotyping, maternal serum screening for down syndrome, risk assessment for early/late-onset preeclampsia, folate metabolism genetic testing, congenital infection screening,carrier scan, thalassemia genetic testing, spinal muscular atrophy genetic testing, and fragile X syndrome genetic testing. It also provides baby genetic testing comprising sensorineural hearing loss genetic testing; congenital central hypoventilation syndrome genetic testing (CCHS); and congenital cytomegalovirus infection testing (CMV). In addition, the company offers cancer screening services, which includes human papillomavirus screening (HPV); and hereditary cancer testing services. Further, it develops precision medicine genetic testing; and offers testing services to patients and carriers with rare disorders. Sofiva Genomics Co.,Ltd. was founded in 2012 and is based in Taipei, Taiwan.
Sofiva Genomics Co.,Ltd. management
2- Dr. Chia-Cheng HungGeneral Manager
- Mr. Fu-Chien ChangFinance Director & Chief Accounting Supervisor